Serine Threonine Protein Kinase PLK1, Pipeline Review, H2 2019 - Leukemia, Breast Cancer, Hodgkin Lymphona & Rhabdomyosarcoma - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 17, 2020--
The “Serine Threonine Protein Kinase PLK1 - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 188.8.131.52) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2019, outlays comprehensive information on the Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 220.127.116.11) - Serine/threonine-protein kinase PLK1 is an enzyme encoded by the PLK1 (polo-like kinase 1) gene. It is highly expressed during mitosis and elevated levels are found in many different types of cancer. Depletion of this protein in cancer cells dramatically inhibited cell proliferation and induced apoptosis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 1, 3 and 1 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Leukemia, Myelodysplastic Syndrome, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Skin Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anal Cancer, Breast Cancer, Cervical Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Human Papillomavirus (HPV) Associated Cancer, Juvenile Myelomonocytic Leukemia (JMML), Lung Cancer, Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Penile Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rhabdomyosarcoma, Sarcomas, Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer (TNBC).
Reasons to buy
Key Topics Covered:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yo5qr8
View source version on businesswire.com:https://www.businesswire.com/news/home/20200117005276/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 01/17/2020 08:53 AM/DISC: 01/17/2020 08:53 AM